within Pharmacolibrary.Drugs.ATC.S;

model S01EX05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 0.04 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EX05</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Netarsudil is a Rho kinase inhibitor used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is approved for topical ophthalmic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for human subjects based on available product labeling and pharmacology reviews, as direct peer-reviewed pharmacokinetic profile studies are not published.</p><h4>References</h4><ol><li><p>Kopczynski, CC, &amp; Heah, T (2018). Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension. <i>Drugs of today (Barcelona, Spain : 1998)</i> 54(8) 467–478. DOI:<a href=&quot;https://doi.org/10.1358/dot.2018.54.8.2849627&quot;>10.1358/dot.2018.54.8.2849627</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30209441/&quot;>https://pubmed.ncbi.nlm.nih.gov/30209441</a></p></li><li><p>Batra, M, et al., &amp; Morsy, MA (2021). Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. <i>European journal of ophthalmology</i> 31(5) 2237–2244. DOI:<a href=&quot;https://doi.org/10.1177/11206721211008783&quot;>10.1177/11206721211008783</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33843288/&quot;>https://pubmed.ncbi.nlm.nih.gov/33843288</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EX05;
